(Total Views: 623)
Posted On: 06/23/2024 5:11:59 PM
Post# of 154604
Pembrolizumab is under clinical development by Merck and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According to GlobalData, Phase II drugs for Recurrent Glioblastoma Multiforme (GBM) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III.
GBM study Conflict?
Anybody think this could have had to do with the delay of the GBM study at Montefiore?
GBM study Conflict?
Anybody think this could have had to do with the delay of the GBM study at Montefiore?
(0)
(0)
